Top Pharmaceutical Companies in Boston, MA (130)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.
Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.
Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.
Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.
Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.
Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.
Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
Agilathon, launched by the founders of Extension Engine, is a strategy and technology services firm focusing on decentralized, mobile clinical trial innovation. We have over 15 years of experience working with industry-leading partners to develop ePRO and eClinical technology solutions across 1000+ diverse clinical trials. Our experienced team collaborates with Contract Research Outsourcing (CRO) and pharmaceutical companies create solutions for...
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
About Enzyvant Enzyvant is a biopharmaceutical company making life-altering impact for people affected by rare disease, where communities are small, and the human need is immense. Enzyvant partners with these communities to accelerate development of transformative medicines, collaborating with academia, industry, physician associations, advocacy groups and government, because strong relationships make bold science possible. Enzyvant has capabilities spanning non-clinical and clinical development...
CVS Health is the leading health solutions company that delivers care in ways no one else can. We reach people in more ways and improve the health of communities across America through our local presence, digital channels and our nearly 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we...
CVS Health's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue rose 7.3% year over year in Q2 2026 and the company raised full‑year 2026 guidance while adjusted operating income increased. Gains reflect improvement across all segments, led by Health Care Benefits.
Diversified Revenue Streams: Gains are attributed to improved purchasing economics and pharmacy mix alongside modest improvement in health care delivery, indicating multiple segments contributing. The integrated model spanning retail pharmacy, PBM, and insurance broadens earnings sources across businesses.
Strong Market Position & Advantage: CVS is the largest U.S. retail pharmacy by prescription revenue and remains top‑tier in PBMs and Medicare plans while operating a major national insurer. Overall corporate scale, including a top‑6 Fortune 500 ranking by revenue, supports purchasing leverage and cross‑segment reach.
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on...
Kymera Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: The company reports $775M in cash as of March 31, 2025 and $1.6B as of December 31, 2025, extending its runway into 2029. An upsized equity raise and milestone receipts further support multi‑year development.
Strategic Partnerships: Kymera has significant collaborations with Sanofi, Gilead, GSK, and Vertex, including a $20M milestone from Sanofi tied to IRAK4 progress. These alliances provide funding, resources, and validation while accelerating key programs in immunology and oncology.
Innovation-Driven Growth: The pipeline features first‑in‑class oral immunology degraders such as KT‑621 (STAT6) with positive Phase 1b atopic dermatitis data and Fast Track, and KT‑579 (IRF5) entering Phase 1 in early 2026. A proprietary platform spanning heterobifunctional degraders and molecular glues enables steady pipeline advancement.
Lyra Therapeutics is a clinical-stage biotechnology company developing long-acting, locally delivered anti-inflammatory implants to treat chronic rhinosinusitis (CRS). The company designs bioabsorbable drug-eluting matrices that release steroid therapy directly to sinonasal tissues for sustained relief, advancing lead candidates (LYR-210 and LYR-220) through late-stage clinical trials and pursuing commercialization and strategic alternatives to benefit CRS patients.
Headquartered in Dedham, Mass., AliMed is a specialty medical supplies manufacturer and distributor with on-site customization capabilities and a vast portfolio of healthcare products designed to improve patient outcomes and experiences. Celebrating 50 years of serving patient needs spanning “hospital to home,” AliMed has built its long history and strong reputation on responsiveness, exceptional customer service, and high-quality offerings. Visit AliMed.com...
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from rare hematologic and musculoskeletal disorders with high unmet medical need
Prudentia’s AI-powered technology accelerates investment in breakthrough therapies that change the world.
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring...
OM1 is an insights-driven technology and data company specializing in Personalized Medicine, Evidence Generation, and RWE Research powered by next-Gen A.I. platforms, regulatory-grade deep longitudinal data, and globally recognized thought leadership. Our unprecedented innovation takes RWE from Bench-to-Practice, delivering unparalleled personalized impact on the outcomes of patients and the advancement of research. We do things differently. We are pushing the boundaries...
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes across oncology, neurology and cardiology. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years.
Lantheus's Top Stability & Growth Strengths
Strong Market Position & Advantage: PYLARIFY is described as the leading PSMA PET agent in the U.S., and DEFINITY is the most utilized ultrasound contrast agent, underscoring category leadership. Management’s 2026 plan emphasizes sustaining PSMA PET leadership and leveraging a broad manufacturing and distribution network.
Diversified Revenue Streams: Portfolio expansion into Alzheimer’s PET via NEURACEQ adds a second commercial PET pillar alongside PSMA and echocardiography contrast. Recent acquisitions and the SPECT divestiture concentrate the company around multiple higher‑growth PET diagnostics.
Future-Ready Strategy: FDA clearance of PYLARIFY TruVu with a phased 4Q26 launch is framed to expand capacity and strengthen supply. Management points to late‑stage catalysts and execution in 2026 as enablers of growth reacceleration from 2027.
Podimetrics is a virtual care management company dedicated to preventing costly and deadly diabetic amputations. We provide high-risk patients our FDA-cleared SmartMat™ through partnerships with payers and at-risk providers, including the Veterans Health Administration. After placing their feet on the mat for just 20 seconds a day, patients’ data are automatically sent to our care management team, which helps address...
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As an organization, Karyopharm is on a mission to improve lives and defeat cancer. In its role as leaders in XPO1 inhibition, Karyopharm delivers on its mission by creating a...
The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for people with cystic fibrosis, a rare, genetic disease in which a defective gene causes a thick buildup of mucus in the lungs, pancreas, and other organs. The buildup of mucus can lead to extensive lung damage, respiratory failure, malnutrition, liver disease, and gastrointestinal issues, among...
Valo is a technology company built to transform the drug discovery and development process using human-centric data and AI-powered computation. Valo is fully integrating human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™...
